• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»traumatic brain injury

How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation

By Soujanya Ravi on May 13, 2026   Pharma & Biotech  

How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation

How is PharmAla Biotech Holdings Inc. positioning APA-01 for traumatic brain injury and neurorehabilitation markets? Read the full PDN analysis.

Why Oragenics, Inc. is betting on CardioDialysis technology to expand its TBI platform

By Soujanya Ravi on May 7, 2026   Pharma & Biotech  

Why Oragenics, Inc. is betting on CardioDialysis technology to expand its TBI platform

Why is Oragenics, Inc. expanding into CardioDialysis for TBI treatment? Explore the strategy, risks, and future implications today.

Alpha Cognition expands ALPHA-1062 into traumatic brain injury, but approval is still a distant goal

By Pallavi Madhiraju on April 2, 2026   Pharma & Biotech  

Alpha Cognition expands ALPHA-1062 into traumatic brain injury, but approval is still a distant goal

Alpha Cognition won a U.S. patent for ALPHA-1062 in TBI. Read why the IP matters, what it changes, and where the biggest risks still remain.

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes